Compare Taskus Inc (TASK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Viatris Inc — how do they compare? Taskus Inc trades at $7.09 (market cap $650.52M), while Viatris Inc trades at $16.19 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 28.7× Taskus Inc's market cap, and Viatris Inc pays a 2.95% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| TASK | VTRS | |
|---|---|---|
Market Cap | $650.52M | $18.69B |
Sector | Technology | Health |
52-Week High | $18.21 | $17.86 |
52-Week Low | $4.57 | $9.49 |
Enterprise Value | $1.02B | $30.81B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $7.30, down 6.65% today, but maintains strong fundamentals with Q2 2026 revenue beating guidance by $10.9 million. The stock shows bullish technical signals with support at $7 and bullish moving averages. Valuation metrics appear attractive with P/E of 6.29 and P/S of 0.55, while profitability remains solid with 8.75% net margin and 25.43% ROE. Recent CFO appointment and AI services growth provide positive catalysts.
The outlook remains positive with analyst consensus favoring Buy ratings (54.55%) and improving cash flow trends. Key opportunities include undervaluation relative to earnings power and AI services expansion. Risks include client concentration and potential earnings volatility. The combination of reasonable valuation and growth momentum supports a constructive view for patient investors.
Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.
While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
